KLRK1 and tuberculosis: Future immunotherapy approaches containing primary NK cells in combination with examined TB-constructs should ensure that sufficient NK cell numbers and a strongly elevated NKG2D expression are available for an efficient receptor–ligand-(NKG2D-ULPB2)-binding as well as for complete eliminations of remaining leukemia cells, especially shown in high-risk patients.